Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine for symptomatic cutaneous or indolent systemic mastocytosis with skin involvement
2024-518594-33-00Phase 3Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of hydroxychloroquine in mastocytosis, cutaneous mastocytosis (CM) and systemic mastocytosis (SM), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Change in mast cell activation symptoms at 12 months. Planned start Nov 2021; status: authorised.
02
Drugs
hydroxychloroquine
03
Conditions
mastocytosiscutaneous mastocytosis (CM)systemic mastocytosis (SM)
Beyond the preview
Go deeper on 2024-518594-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518594-33-00.